- Home
- MNKD vs PRCT Comparison
MNKD vs PRCT Comparison
Compare MNKD & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNKD | PRCT |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNKD | PRCT |
|---|---|---|
| Price | $5.72 | $28.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $10.08 | ★ $51.13 |
| AVG Volume (30 Days) | ★ 4.0M | 1.2M |
| Earning Date | 02-23-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.47 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $313,787,000.00 | $299,907,000.00 |
| Revenue This Year | $21.29 | $48.30 |
| Revenue Next Year | $25.53 | $29.44 |
| P/E Ratio | $59.56 | ★ N/A |
| Revenue Growth | 17.43 | ★ 50.07 |
| 52 Week Low | $3.38 | $26.66 |
| 52 Week High | $6.51 | $70.80 |
Technical Indicators
Market Signals| Indicator | MNKD | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 42.78 |
| Support Level | $5.47 | $26.93 |
| Resistance Level | $6.05 | $30.02 |
| Average True Range (ATR) | 0.31 | 1.63 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 34.71 | 39.86 |
Price Performance
Historical ComparisonAbout MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.